2023 Q1 Form 10-K Financial Statement
#000186078223000038 Filed on March 16, 2023
Income Statement
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
Revenue | $41.62M | $56.18M | $91.50M |
YoY Change | 393.78% | 250.36% | 67.81% |
Cost Of Revenue | $641.0K | $15.33M | $1.726M |
YoY Change | 25.44% | 3674.63% | -31.43% |
Gross Profit | $40.98M | $40.85M | $89.77M |
YoY Change | 417.55% | 161.4% | 72.62% |
Gross Profit Margin | 98.46% | 72.72% | 98.11% |
Selling, General & Admin | $20.72M | $18.70M | $79.45M |
YoY Change | -13.16% | -23.61% | -15.03% |
% of Gross Profit | 50.56% | 45.78% | 88.5% |
Research & Development | $68.25M | $49.31M | $248.7M |
YoY Change | -1.44% | -17.18% | -5.04% |
% of Gross Profit | 166.53% | 120.71% | 277.08% |
Depreciation & Amortization | $2.255M | $2.325M | $11.53M |
YoY Change | -36.12% | -34.23% | -29.46% |
% of Gross Profit | 5.5% | 5.69% | 12.85% |
Operating Expenses | $88.97M | $68.06M | $328.2M |
YoY Change | -4.45% | -18.97% | -7.67% |
Operating Profit | -$51.71M | -$27.21M | -$263.1M |
YoY Change | -42.91% | -60.2% | -16.18% |
Interest Expense | $2.049M | $1.491M | $2.932M |
YoY Change | 1681.74% | 1594.32% | 3231.82% |
% of Operating Profit | |||
Other Income/Expense, Net | $2.643M | $2.561M | $6.055M |
YoY Change | -44.5% | -64.95% | -72.03% |
Pretax Income | -$47.02M | -$23.16M | -$254.2M |
YoY Change | -45.14% | -62.02% | -13.02% |
Income Tax | $0.00 | -$17.00K | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$47.00M | -$23.14M | -$254.2M |
YoY Change | -45.16% | -62.05% | -13.02% |
Net Earnings / Revenue | -112.92% | -41.2% | -277.77% |
Basic Earnings Per Share | -$1.08 | -$7.13 | |
Diluted Earnings Per Share | -$1.08 | -$0.60 | -$7.13 |
COMMON SHARES | |||
Basic Shares Outstanding | 50.19M shares | 37.92M shares | 35.64M shares |
Diluted Shares Outstanding | 43.47M shares | 35.64M shares |
Balance Sheet
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $339.9M | $266.3M | $266.3M |
YoY Change | -10.04% | 0.46% | 0.46% |
Cash & Equivalents | $193.6M | $71.03M | $71.03M |
Short-Term Investments | $146.3M | $195.2M | $195.2M |
Other Short-Term Assets | $8.635M | $13.65M | $13.65M |
YoY Change | -52.03% | 43.52% | 43.52% |
Inventory | |||
Prepaid Expenses | $8.635M | $13.65M | |
Receivables | $41.25M | $20.96M | $20.96M |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $389.8M | $300.9M | $300.9M |
YoY Change | -5.57% | 3.2% | 3.2% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $59.15M | $55.74M | $296.6M |
YoY Change | 68.83% | 59.64% | -4.45% |
Goodwill | $12.06M | $12.06M | |
YoY Change | 0.0% | 0.0% | |
Intangibles | $7.125M | $7.302M | |
YoY Change | -18.79% | -26.18% | |
Long-Term Investments | $1.432M | $1.414M | $1.414M |
YoY Change | -98.08% | -98.54% | -98.54% |
Other Assets | $37.59M | $38.39M | $38.39M |
YoY Change | -0.41% | -0.52% | -0.52% |
Total Long-Term Assets | $352.6M | $355.8M | $355.8M |
YoY Change | -19.7% | -24.0% | -24.0% |
TOTAL ASSETS | |||
Total Short-Term Assets | $389.8M | $300.9M | $300.9M |
Total Long-Term Assets | $352.6M | $355.8M | $355.8M |
Total Assets | $742.4M | $656.7M | $656.7M |
YoY Change | -12.85% | -13.56% | -13.56% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $13.40M | $7.208M | $7.208M |
YoY Change | -1.82% | 19.65% | 19.65% |
Accrued Expenses | $55.05M | $65.84M | $65.84M |
YoY Change | -19.68% | 1.02% | 1.02% |
Deferred Revenue | $8.480M | $3.000M | |
YoY Change | 69.6% | -40.0% | |
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $76.93M | $79.79M | $79.79M |
YoY Change | -27.64% | -18.9% | -18.9% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $2.401M | $2.397M | $266.4M |
YoY Change | -1.23% | 12.96% | -11.63% |
Total Long-Term Liabilities | $2.401M | $2.397M | $266.4M |
YoY Change | -1.23% | 12.96% | -11.63% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $76.93M | $79.79M | $79.79M |
Total Long-Term Liabilities | $2.401M | $2.397M | $266.4M |
Total Liabilities | $341.1M | $346.2M | $346.2M |
YoY Change | -15.67% | -13.42% | -13.42% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$340.7M | -$293.6M | |
YoY Change | 172.09% | 643.52% | |
Common Stock | $5.000K | $4.000K | |
YoY Change | 25.0% | 100.0% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $401.3M | $310.5M | $310.5M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $742.4M | $656.7M | $656.7M |
YoY Change | -12.85% | -13.56% | -13.56% |
Cashflow Statement
Concept | 2023 Q1 | 2022 Q4 | 2022 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$47.00M | -$23.14M | -$254.2M |
YoY Change | -45.16% | -62.05% | -13.02% |
Depreciation, Depletion And Amortization | $2.255M | $2.325M | $11.53M |
YoY Change | -36.12% | -34.23% | -29.46% |
Cash From Operating Activities | -$49.10M | -$55.48M | -$237.1M |
YoY Change | -33.74% | -3.41% | 14.56% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $6.079M | $3.166M | $22.84M |
YoY Change | 69.57% | -424.72% | 97.34% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | $50.88M | $2.634M | $34.54M |
YoY Change | 5.26% | -92.47% | -1.28% |
Cash From Investing Activities | $44.80M | -$532.0K | $11.70M |
YoY Change | 0.11% | -101.56% | -24.1% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | |||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | $127.1M | 232.0K | $166.2M |
YoY Change | -25.29% | -99.88% | -53.16% |
NET CHANGE | |||
Cash From Operating Activities | -$49.10M | -55.48M | -$237.1M |
Cash From Investing Activities | $44.80M | -532.0K | $11.70M |
Cash From Financing Activities | $127.1M | 232.0K | $166.2M |
Net Change In Cash | $122.8M | -55.78M | -$59.21M |
YoY Change | -12.78% | -134.17% | -136.26% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$49.10M | -$55.48M | -$237.1M |
Capital Expenditures | $6.079M | $3.166M | $22.84M |
Free Cash Flow | -$55.18M | -$58.65M | -$260.0M |
YoY Change | -28.97% | 3.86% | 18.94% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2022 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2022 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001860782 | |
CY2022 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2022 | |
CY2022 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
FY | |
CY2021Q3 | tsvt |
Common Stock Convertible Conversion Ratio
CommonStockConvertibleConversionRatio
|
0.3333 | |
CY2022 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | segment |
CY2022Q4 | tsvt |
Common Stock Convertible Conversion Ratio
CommonStockConvertibleConversionRatio
|
0.3333 | |
CY2022 | dei |
Entity Shell Company
EntityShellCompany
|
false | |
CY2022Q2 | dei |
Entity Public Float
EntityPublicFloat
|
496765830 | usd |
CY2023Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
50189753 | shares |
CY2022 | dei |
Auditor Firm
AuditorFirmId
|
42 | |
CY2022 | dei |
Auditor Name
AuditorName
|
Ernst & Young LLP | |
CY2022 | dei |
Auditor Location
AuditorLocation
|
Boston, Massachusetts | |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
71032000 | usd |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
130414000 | usd |
CY2022Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
195238000 | usd |
CY2021Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
134643000 | usd |
CY2022Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
13652000 | usd |
CY2021Q4 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
9512000 | usd |
CY2022Q4 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
20960000 | usd |
CY2021Q4 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
16995000 | usd |
CY2022Q4 | us-gaap |
Assets Current
AssetsCurrent
|
300882000 | usd |
CY2021Q4 | us-gaap |
Assets Current
AssetsCurrent
|
291564000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
55735000 | usd |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
34913000 | usd |
CY2022Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
1414000 | usd |
CY2021Q4 | us-gaap |
Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
|
97124000 | usd |
CY2022Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
7302000 | usd |
CY2021Q4 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
9892000 | usd |
CY2022Q4 | us-gaap |
Goodwill
Goodwill
|
12056000 | usd |
CY2021Q4 | us-gaap |
Goodwill
Goodwill
|
12056000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
240885000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
275534000 | usd |
CY2022Q4 | tsvt |
Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
|
38391000 | usd |
CY2021Q4 | tsvt |
Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
|
38592000 | usd |
CY2022Q4 | us-gaap |
Assets
Assets
|
656665000 | usd |
CY2021Q4 | us-gaap |
Assets
Assets
|
759675000 | usd |
CY2022Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
7208000 | usd |
CY2021Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
6024000 | usd |
CY2022Q4 | tsvt |
Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
|
54678000 | usd |
CY2021Q4 | tsvt |
Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
|
55410000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
11164000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
9769000 | usd |
CY2022Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
3000000 | usd |
CY2021Q4 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
5000000 | usd |
CY2022Q4 | tsvt |
Collaboration Research Advancement Current
CollaborationResearchAdvancementCurrent
|
3744000 | usd |
CY2021Q4 | tsvt |
Collaboration Research Advancement Current
CollaborationResearchAdvancementCurrent
|
22185000 | usd |
CY2022Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
79794000 | usd |
CY2021Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
98388000 | usd |
CY2022Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
5000000 | usd |
CY2021Q4 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
25762000 | usd |
CY2022Q4 | tsvt |
Collaboration Research Advancement Non Current
CollaborationResearchAdvancementNonCurrent
|
0 | usd |
CY2021Q4 | tsvt |
Collaboration Research Advancement Non Current
CollaborationResearchAdvancementNonCurrent
|
1135000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
259008000 | usd |
CY2021Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
272446000 | usd |
CY2022Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
2397000 | usd |
CY2021Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
2122000 | usd |
CY2022Q4 | us-gaap |
Liabilities
Liabilities
|
346199000 | usd |
CY2021Q4 | us-gaap |
Liabilities
Liabilities
|
399853000 | usd |
CY2022Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2021Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
usd | |
CY2022Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.1000 | |
CY2021Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.1000 | |
CY2021Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2021Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
0 | usd |
CY2022Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2021Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
37928000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
37928000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23585000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23585000 | shares |
CY2022Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
4000 | usd |
CY2021Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
2000 | usd |
CY2022Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
606986000 | usd |
CY2021Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
400026000 | usd |
CY2022Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-2877000 | usd |
CY2021Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-712000 | usd |
CY2022Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-293647000 | usd |
CY2021Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-39494000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
310466000 | usd |
CY2021Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
359822000 | usd |
CY2022Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
656665000 | usd |
CY2021Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
759675000 | usd |
CY2022 | us-gaap |
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
|
32358000 | usd |
CY2021 | us-gaap |
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
|
26921000 | usd |
CY2020 | us-gaap |
Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
|
115594000 | usd |
CY2022 | us-gaap |
Revenues
Revenues
|
91496000 | usd |
CY2021 | us-gaap |
Revenues
Revenues
|
54522000 | usd |
CY2020 | us-gaap |
Revenues
Revenues
|
248122000 | usd |
CY2022 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
248735000 | usd |
CY2021 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
252617000 | usd |
CY2020 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
296467000 | usd |
CY2022 | tsvt |
Manufacturing Costs Under Commercial Arrangements
ManufacturingCostsUnderCommercialArrangements
|
14851000 | usd |
CY2021 | tsvt |
Manufacturing Costs Under Commercial Arrangements
ManufacturingCostsUnderCommercialArrangements
|
9320000 | usd |
CY2020 | tsvt |
Manufacturing Costs Under Commercial Arrangements
ManufacturingCostsUnderCommercialArrangements
|
0 | usd |
CY2022 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
79450000 | usd |
CY2021 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
93506000 | usd |
CY2020 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
90897000 | usd |
CY2021 | tsvt |
Income Loss From Collaborative Arrangements
IncomeLossFromCollaborativeArrangements
|
-10071000 | usd |
CY2020 | tsvt |
Income Loss From Collaborative Arrangements
IncomeLossFromCollaborativeArrangements
|
0 | usd |
CY2022 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-263140000 | usd |
CY2022 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
2932000 | usd |
CY2021 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
88000 | usd |
CY2022 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
6055000 | usd |
CY2021 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
21647000 | usd |
CY2020 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
18056000 | usd |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-254153000 | usd |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-292213000 | usd |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-120114000 | usd |
CY2022 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2021 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2020 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
0 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-254153000 | usd |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-292213000 | usd |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-120114000 | usd |
CY2022 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-7.13 | |
CY2022 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-7.13 | |
CY2021 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-12.44 | |
CY2021 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-12.44 | |
CY2020 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-5.14 | |
CY2020 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-5.14 | |
CY2022 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
35637000 | shares |
CY2022 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
35637000 | shares |
CY2021 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
23499000 | shares |
CY2021 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
23499000 | shares |
CY2020 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
23369000 | shares |
CY2020 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
23369000 | shares |
CY2022 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
0 | usd |
CY2021 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
0 | usd |
CY2020 | us-gaap |
Other Comprehensive Income Loss Tax
OtherComprehensiveIncomeLossTax
|
0 | usd |
CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-2165000 | usd |
CY2021 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-712000 | usd |
CY2020 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
0 | usd |
CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-2165000 | usd |
CY2021 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-712000 | usd |
CY2020 | us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
0 | usd |
CY2022 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-256318000 | usd |
CY2021 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-292925000 | usd |
CY2020 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-120114000 | usd |
CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
43692000 | usd |
CY2020 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
60997000 | usd |
CY2020 | tsvt |
Transfers From Transfers To Net Parent Investment
TransfersFromTransfersToNetParentInvestment
|
90054000 | usd |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-120114000 | usd |
CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
74629000 | usd |
CY2021 | tsvt |
Share Based Payment Arrangement Increase For Cost Recognition From Parent
ShareBasedPaymentArrangementIncreaseForCostRecognitionFromParent
|
44626000 | usd |
CY2021 | tsvt |
Transfers From Transfers To Net Parent Investment
TransfersFromTransfersToNetParentInvestment
|
517706000 | usd |
CY2021 | tsvt |
Stock Issued During Period Value Consummation Of Spin Off Transaction
StockIssuedDuringPeriodValueConsummationOfSpinOffTransaction
|
0 | usd |
CY2021 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
6544000 | usd |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-292213000 | usd |
CY2022 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
2000 | shares |
CY2022 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
17000 | usd |
CY2022 | us-gaap |
Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
|
13934000 | shares |
CY2022 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
165533000 | usd |
CY2022 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
41040000 | usd |
CY2022 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
372000 | usd |
CY2022 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
-2165000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-254153000 | usd |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
310466000 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-254153000 | usd |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-292213000 | usd |
CY2022 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
232000 | usd |
CY2021 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
439000 | usd |
CY2020 | us-gaap |
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
|
-6468000 | usd |
CY2022 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
11533000 | usd |
CY2021 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
16350000 | usd |
CY2020 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
13188000 | usd |
CY2022 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
41040000 | usd |
CY2021 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
54629000 | usd |
CY2020 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
60997000 | usd |
CY2022 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-85000 | usd |
CY2021 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-430000 | usd |
CY2020 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-73000 | usd |
CY2022 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
8356000 | usd |
CY2021 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1578000 | usd |
CY2020 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1526000 | usd |
CY2022 | tsvt |
Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
|
34649000 | usd |
CY2021 | tsvt |
Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
|
15541000 | usd |
CY2020 | tsvt |
Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
|
13764000 | usd |
CY2022 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
327000 | usd |
CY2021 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-6000 | usd |
CY2020 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-13240000 | usd |
CY2022 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-8110000 | usd |
CY2021 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
15733000 | usd |
CY2020 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-7479000 | usd |
CY2022 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-12042000 | usd |
CY2021 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-16199000 | usd |
CY2020 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-10960000 | usd |
CY2022 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-22762000 | usd |
CY2021 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
4180000 | usd |
CY2020 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
8317000 | usd |
CY2022 | tsvt |
Increase Decrease In Collaboration Research Advancement
IncreaseDecreaseInCollaborationResearchAdvancement
|
19577000 | usd |
CY2021 | tsvt |
Increase Decrease In Collaboration Research Advancement
IncreaseDecreaseInCollaborationResearchAdvancement
|
7496000 | usd |
CY2020 | tsvt |
Increase Decrease In Collaboration Research Advancement
IncreaseDecreaseInCollaborationResearchAdvancement
|
7397000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-237134000 | usd |
CY2021 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-207034000 | usd |
CY2020 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-67793000 | usd |
CY2022 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
22842000 | usd |
CY2021 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
11575000 | usd |
CY2020 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
22261000 | usd |
CY2022 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
145908000 | usd |
CY2021 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
0 | usd |
CY2020 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
0 | usd |
CY2022 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
180447000 | usd |
CY2021 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
34986000 | usd |
CY2020 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
0 | usd |
CY2022 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | usd |
CY2021 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
8000000 | usd |
CY2020 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
11697000 | usd |
CY2021 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
15411000 | usd |
CY2020 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-22261000 | usd |
CY2022 | us-gaap |
Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
|
0 | usd |
CY2021 | us-gaap |
Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
|
354889000 | usd |
CY2020 | us-gaap |
Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
|
90054000 | usd |
CY2022 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
165533000 | usd |
CY2021 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
0 | usd |
CY2020 | us-gaap |
Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
|
0 | usd |
CY2022 | tsvt |
Proceeds From Stock Options Exercised And Stock Plans
ProceedsFromStockOptionsExercisedAndStockPlans
|
696000 | usd |
CY2021 | tsvt |
Proceeds From Stock Options Exercised And Stock Plans
ProceedsFromStockOptionsExercisedAndStockPlans
|
0 | usd |
CY2020 | tsvt |
Proceeds From Stock Options Exercised And Stock Plans
ProceedsFromStockOptionsExercisedAndStockPlans
|
0 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
166229000 | usd |
CY2021 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
354889000 | usd |
CY2020 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
90054000 | usd |
CY2022 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-59208000 | usd |
CY2021 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
163266000 | usd |
CY2020 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
0 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
163266000 | usd |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | usd |
CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | usd |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
104058000 | usd |
CY2021Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
163266000 | usd |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | usd |
CY2022Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
71032000 | usd |
CY2021Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
130414000 | usd |
CY2020Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
0 | usd |
CY2022Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
33026000 | usd |
CY2021Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
32852000 | usd |
CY2020Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
0 | usd |
CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
0 | usd |
CY2022 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
10896000 | usd |
CY2021 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
3703000 | usd |
CY2020 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
2039000 | usd |
CY2022 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | usd |
CY2021 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
0 | usd |
CY2020 | us-gaap |
Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
|
4989000 | usd |
CY2022 | tsvt |
Noncash Or Part Noncash Transfer To Net Parent Investment
NoncashOrPartNoncashTransferToNetParentInvestment
|
0 | usd |
CY2021 | tsvt |
Noncash Or Part Noncash Transfer To Net Parent Investment
NoncashOrPartNoncashTransferToNetParentInvestment
|
110300000 | usd |
CY2020 | tsvt |
Noncash Or Part Noncash Transfer To Net Parent Investment
NoncashOrPartNoncashTransferToNetParentInvestment
|
0 | usd |
CY2022 | tsvt |
Increase Of Right Of Use Asset And Associated Lease Liability Due To Reassessment
IncreaseOfRightOfUseAssetAndAssociatedLeaseLiabilityDueToReassessment
|
0 | usd |
CY2021 | tsvt |
Increase Of Right Of Use Asset And Associated Lease Liability Due To Reassessment
IncreaseOfRightOfUseAssetAndAssociatedLeaseLiabilityDueToReassessment
|
174618000 | usd |
CY2020 | tsvt |
Increase Of Right Of Use Asset And Associated Lease Liability Due To Reassessment
IncreaseOfRightOfUseAssetAndAssociatedLeaseLiabilityDueToReassessment
|
0 | usd |
CY2022 | us-gaap |
Stock Issued1
StockIssued1
|
0 | usd |
CY2021 | us-gaap |
Stock Issued1
StockIssued1
|
6544000 | usd |
CY2020 | us-gaap |
Stock Issued1
StockIssued1
|
0 | usd |
CY2022 | us-gaap |
Nature Of Operations
NatureOfOperations
|
Description of the business<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy bio, Inc. (the “Company” or “2seventy bio”) is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The Company’s approach combines its expertise in T cell engineering technology and lentiviral vector gene delivery approaches, experience in research, development, and manufacturing of cell therapies and a suite of technologies that can be selectively deployed to develop highly innovative, targeted cellular therapies for patients with cancer. The Company is advancing multiple preclinical and clinical programs in oncology and, together with Bristol Myers Squibb (“BMS”), delivering the first FDA-approved CAR T therapy in multiple myeloma, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abecma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (idecabtagene vicleucel, or ide-cel), to patients in the United States. Please refer to Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative arrangements and strategic partnerships</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the collaboration with BMS. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2seventy bio Securities Corporation is a wholly-owned subsidiary of the Company which was incorporated in Massachusetts on December 13, 2021 and was granted securities corporation status in Massachusetts for the 2021 tax year. 2seventy bio Securities Corporation has no employees.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties similar to other companies in the biotechnology industry. There can be no assurance that the Company’s preclinical studies and clinical trials will be successfully completed, that it will maintain protection of proprietary technology, or that it will obtain the necessary government regulatory approvals for its product candidates or those of its collaborators. Even if approved, these product candidates may not be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnology companies. Additionally, the Company is dependent on key personnel and on third party organizations such as financial institutions, collaborators, and contract manufacturing organizations. </span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The separation from bluebird bio, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, bluebird bio, Inc. (“bluebird bio”) announced its plans to separate its oncology portfolio and programs from its severe genetic disease portfolio and programs, and spin off its oncology portfolio and programs into a separate, publicly traded company. In furtherance of this plan, 2seventy bio was incorporated as a Delaware corporation in April 2021, and in September 2021, bluebird bio’s board of directors approved the distribution of all of the issued and outstanding shares of 2seventy bio common stock on the basis of one share of 2seventy bio common stock for every three shares of bluebird bio common stock issued and outstanding on October 19, 2021, the record date for the distribution. As a result of the distribution, which occurred on November 4, 2021, 2seventy bio became an independent, publicly traded company.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 3, 2021, the Company also entered into a separation agreement with bluebird bio, which is referred to in this annual report as the “Separation Agreement”, as well as various other agreements with bluebird bio, including a tax matters agreement, an employee matters agreement, an intellectual property license agreement, a transition services agreement under which 2seventy bio temporarily receives certain services from bluebird bio, and a second transition services agreement under which 2seventy bio temporarily provides certain services to bluebird bio. These agreements also govern certain of 2seventy bio’s relationships with bluebird bio after the separation. For additional information regarding the Separation Agreement and the other related agreements, refer to Note 14, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-party transactions.</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going concern</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with Accounting Standards Codification (“ASC”) 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the consolidated and combined financial </span></div>statements are issued. The Company has incurred losses and has experienced negative operating cash flows for all historical periods presented. During the year ended December 31, 2022, the Company incurred a net loss of $254.2 million and used $237.1 million of cash in operations. The Company expects to continue to generate operating losses and negative operating cash flows for the next few years. The Company's continued operations are dependent on its ability to raise additional funding. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company had cash, cash equivalents and marketable securities of $267.7 million. In January 2023, the Company entered into a Share Purchase Agreement with Regeneron Pharmaceuticals, Inc. (“Regeneron”) pursuant to which it sold 1,114,827 shares of its common stock to Regeneron for an aggregate cash price of approximately $20.0 million. In March 2023, the Company sold 10.9 million shares of common stock through an underwritten public offering at a price per share of $11.50. This resulted in aggregate gross proceeds to the Company of approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses. Based on its current operating plans, including with respect to the ongoing commercialization of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abecma</span>, the Company expects that its cash, cash equivalents and marketable securities (including amounts received from the transactions discussed above), will be sufficient to fund current planned operations for at least the next twelve months from the date of filing this Annual Report on Form 10-K. The Company may, in the future, pursue additional cash resources through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances or licensing arrangements with third parties. This includes the potential sale of shares of its common stock of up to $150.0 million in gross proceeds under the at-the-market (“ATM”) facility established in November 2022 with Cowen and Company, LLC. No sales of common stock have occurred under this ATM as of the date of this Annual Report on Form 10-K. | |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-254200000 | usd |
CY2022 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-237100000 | usd |
CY2022Q4 | tsvt |
Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
|
267700000 | usd |
CY2021 | us-gaap |
Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
|
354900000 | usd |
CY2021Q4 | tsvt |
Spinoff Transaction Recognized Identifiable Assets Acquired And Liabilities Assumed Net
SpinoffTransactionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
|
384500000 | usd |
CY2022 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates and judgments are used in the following areas, among others: allocations of revenue, expenses, assets and liabilities from bluebird bio's historical consolidated financial statements to the Company for periods prior to the separation, future undiscounted cash flows and subsequent fair value estimates used to assess potential and measure any impairment of long-lived assets, including goodwill and intangible assets, the measurement of right-of-use assets and lease liabilities, contingent consideration, stock-based compensation expense, accrued expenses, income taxes, and the assessment of the Company's ability to fund its operations for at least the next twelve months from the date of issuance of these financial statements. In addition, estimates and judgments are used in the Company’s accounting for its revenue-generating arrangements, in particular as it relates to determining the stand-alone selling price of performance obligations, evaluating whether an option to acquire additional goods and services represents a material right, estimating the total transaction price, including estimating variable consideration and the probability of achieving future potential development and regulatory milestones, assessing the period of performance over which revenue may be recognized, and accounting for modifications to revenue-generating arrangements.</span></div> | |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
565000 | usd |
CY2022 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:9pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of credit risk and off-balance sheet risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that subject the Company to credit risk primarily consist of cash and cash equivalents, available-for-sale securities, and accounts receivable. Deposits are maintained with banks in the United States and such amounts may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on such accounts, and does not believe it is exposed to any unusual credit risk beyond the normal credit risk currently associated with commercial banking relationships. Cash deposits are insured by the Federal Deposit Insurance Corporations (“FDIC”) up to $250,000. The Company has cash deposits in excess of the FDIC insured limit. The Company’s marketable securities, which primarily consist of U.S. government agency securities and treasuries, corporate bonds and commercial paper, potentially subject the Company to concentrations of credit risk. </span></div>The Company has adopted an investment policy that limits the amounts the Company may invest in any one type of investment and requires all investments held by the Company to be at least AA+/Aa1 rated, thereby reducing credit risk exposure. The Company’s accounts receivable balance primarily consists of amounts owed from collaborative arrangement partners and royalties receivable under out-license agreements with various third parties. The Company monitors economic conditions to identify facts or circumstances that may indicate that any of its accounts receivable are at risk of collection. | |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
0 | usd |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
0 | usd |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
160130000 | usd |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
|
565000 | usd |
CY2022Q4 | us-gaap |
Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
|
0 | usd |
CY2022Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
3416000 | usd |
CY2021Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
8794000 | usd |
CY2022Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
54678000 | usd |
CY2022 | tsvt |
Contract With Customer Liability Revenue Recognized Including Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
|
32358000 | usd |
CY2021 | tsvt |
Contract With Customer Liability Revenue Recognized Including Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
|
26921000 | usd |
CY2020 | tsvt |
Contract With Customer Liability Revenue Recognized Including Opening Balance
ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance
|
115594000 | usd |
CY2022Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
13094000 | usd |
CY2021Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
6768000 | usd |
CY2022Q4 | tsvt |
Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
|
1619000 | usd |
CY2021Q4 | tsvt |
Accrued Clinical And Contract Research Organization Costs Current
AccruedClinicalAndContractResearchOrganizationCostsCurrent
|
3229000 | usd |
CY2022Q4 | tsvt |
Accrued Collaboration Research Costs Current
AccruedCollaborationResearchCostsCurrent
|
2005000 | usd |
CY2021Q4 | tsvt |
Accrued Collaboration Research Costs Current
AccruedCollaborationResearchCostsCurrent
|
2576000 | usd |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
0 | shares |
CY2022Q4 | tsvt |
Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
|
1498000 | usd |
CY2021Q4 | tsvt |
Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
|
2241000 | usd |
CY2022Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
239000 | usd |
CY2021Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1688000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
198754000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
6000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2108000 | usd |
CY2022Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
196652000 | usd |
CY2021Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
232332000 | usd |
CY2021Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
0 | usd |
CY2021Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
565000 | usd |
CY2021Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
231767000 | usd |
CY2022Q4 | us-gaap |
Interest Receivable
InterestReceivable
|
300000 | usd |
CY2021Q4 | us-gaap |
Interest Receivable
InterestReceivable
|
400000 | usd |
CY2021 | tsvt |
Interest Receivable Write Off
InterestReceivableWriteOff
|
0 | usd |
CY2022 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
91385000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
278000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
88674000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
1830000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
180059000 | usd |
CY2022Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
|
2108000 | usd |
CY2021Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
160130000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
103573000 | usd |
CY2021Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
74991000 | usd |
CY2022Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
47838000 | usd |
CY2021Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
40078000 | usd |
CY2022Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
55735000 | usd |
CY2021Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
34913000 | usd |
CY2022 | us-gaap |
Depreciation
Depreciation
|
8900000 | usd |
CY2021 | us-gaap |
Depreciation
Depreciation
|
12100000 | usd |
CY2020 | us-gaap |
Depreciation
Depreciation
|
9400000 | usd |
CY2022Q4 | tsvt |
Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
|
17962000 | usd |
CY2021Q4 | tsvt |
Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
|
5459000 | usd |
CY2022Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
14845000 | usd |
CY2021Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
24655000 | usd |
CY2021Q4 | us-gaap |
Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
|
55410000 | usd |
CY2022 | tsvt |
Salary And Wage Bonus Payout Period
SalaryAndWageBonusPayoutPeriod
|
P6M | |
CY2022 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
33738000 | usd |
CY2021 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
24838000 | usd |
CY2020 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
22454000 | usd |
CY2022 | us-gaap |
Lease Cost
LeaseCost
|
33738000 | usd |
CY2021 | us-gaap |
Lease Cost
LeaseCost
|
24838000 | usd |
CY2020 | us-gaap |
Lease Cost
LeaseCost
|
22454000 | usd |
CY2022 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
27140000 | usd |
CY2021 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
25489000 | usd |
CY2020 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
19632000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P10Y9M18D | |
CY2021Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P11Y9M18D | |
CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P6Y4M24D | |
CY2022Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0547 | |
CY2021Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0547 | |
CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0672 | |
CY2022 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
43900000 | usd |
CY2021 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
34500000 | usd |
CY2020 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
32500000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
27861000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
28672000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
29498000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
32920000 | usd |
CY2022Q4 | tsvt |
Lessee Operating Lease Liability To Be Paid Year Five And Thereafter
LesseeOperatingLeaseLiabilityToBePaidYearFiveAndThereafter
|
250383000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
369334000 | usd |
CY2022Q4 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
99162000 | usd |
CY2022Q4 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
270172000 | usd |
CY2020 | tsvt |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
0.003 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
|
-0.025 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
|
0.003 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent
EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
|
-0.041 | |
CY2022Q4 | us-gaap |
Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
|
16008000 | usd |
CY2022Q4 | us-gaap |
Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
|
15750000 | usd |
CY2022Q4 | us-gaap |
Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
|
0 | usd |
CY2022Q4 | tsvt |
Purchase Obligation To Be Paid Year Four And Thereafter
PurchaseObligationToBePaidYearFourAndThereafter
|
0 | usd |
CY2022Q4 | us-gaap |
Purchase Obligation
PurchaseObligation
|
31758000 | usd |
CY2022Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
200000000 | shares |
CY2022Q4 | tsvt |
Common Stock Number Of Votes Per Common Share
CommonStockNumberOfVotesPerCommonShare
|
1 | vote |
CY2022Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
37900000 | shares |
CY2022Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
37900000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
23600000 | shares |
CY2021Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
23600000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
10000000 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2021Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
CY2022Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
CY2022Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
6689000 | shares |
CY2021Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
5686000 | shares |
CY2022 | tsvt |
Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
|
0.032 | |
CY2021 | tsvt |
Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
|
0.002 | |
CY2020 | tsvt |
Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
|
0.138 | |
CY2022 | tsvt |
Effective Income Tax Rate Reconciliation Officer Compensation Limitation
EffectiveIncomeTaxRateReconciliationOfficerCompensationLimitation
|
-0.012 | |
CY2021 | tsvt |
Effective Income Tax Rate Reconciliation Officer Compensation Limitation
EffectiveIncomeTaxRateReconciliationOfficerCompensationLimitation
|
-0.004 | |
CY2020 | tsvt |
Effective Income Tax Rate Reconciliation Officer Compensation Limitation
EffectiveIncomeTaxRateReconciliationOfficerCompensationLimitation
|
-0.016 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
|
-0.002 | |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
38600000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
31298000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
7302000 | usd |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
38600000 | usd |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
28708000 | usd |
CY2021Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
9892000 | usd |
CY2022 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
2600000 | usd |
CY2021 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
4300000 | usd |
CY2020 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
3800000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
|
708000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
|
708000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
|
708000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
|
708000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
|
708000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
|
3762000 | usd |
CY2022Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
7302000 | usd |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
|
1500000 | usd |
CY2021Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
|
1300000 | usd |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
41000000 | usd |
CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
54600000 | usd |
CY2020 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
61000000 | usd |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
41040000 | usd |
CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
54629000 | usd |
CY2020 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
60997000 | usd |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
|
0 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Contingencies
EffectiveIncomeTaxRateReconciliationTaxContingencies
|
-0.011 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.006 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
-0.011 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
|
0 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.013 | |
CY2022 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
41040000 | usd |
CY2021 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
54629000 | usd |
CY2020 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
60997000 | usd |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
|
0.789 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
|
P6Y1M6D | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
|
0.018 | |
CY2022 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0.000 | |
CY2022 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
|
5500000 | usd |
CY2021Q4 | tsvt |
Number Of Transition Services Agreements
NumberOfTransitionServicesAgreements
|
2 | agreement |
CY2021Q4 | tsvt |
Transition Services Agreement Initial Term
TransitionServicesAgreementInitialTerm
|
P2Y | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.274 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.648 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.321 | |
CY2022 | tsvt |
Effective Income Tax Rate Reconciliation Spin Off Adjustment Percent
EffectiveIncomeTaxRateReconciliationSpinOffAdjustmentPercent
|
0 | |
CY2021 | tsvt |
Effective Income Tax Rate Reconciliation Spin Off Adjustment Percent
EffectiveIncomeTaxRateReconciliationSpinOffAdjustmentPercent
|
-0.854 | |
CY2020 | tsvt |
Effective Income Tax Rate Reconciliation Spin Off Adjustment Percent
EffectiveIncomeTaxRateReconciliationSpinOffAdjustmentPercent
|
0 | |
CY2022 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
3200000 | usd |
CY2021 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
2400000 | usd |
CY2020 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
2200000 | usd |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-254153000 | usd |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-292213000 | usd |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
|
-120114000 | usd |
CY2022 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
0 | usd |
CY2021 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
0 | usd |
CY2020 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
|
0 | usd |
CY2022 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-254153000 | usd |
CY2021 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-292213000 | usd |
CY2020 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-120114000 | usd |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.210 | |
CY2022 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.066 | |
CY2021 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.006 | |
CY2020 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.038 | |
CY2022 | tsvt |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.002 | |
CY2021 | tsvt |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
0 | |
CY2022 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | |
CY2021 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | |
CY2020 | us-gaap |
Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
|
0 | |
CY2022Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
27251000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
12142000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
10071000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
|
466000 | usd |
CY2022Q4 | tsvt |
Deferred Tax Assets Capitalized License Fee And Research And Development Expenses
DeferredTaxAssetsCapitalizedLicenseFeeAndResearchAndDevelopmentExpenses
|
11888000 | usd |
CY2021Q4 | tsvt |
Deferred Tax Assets Capitalized License Fee And Research And Development Expenses
DeferredTaxAssetsCapitalizedLicenseFeeAndResearchAndDevelopmentExpenses
|
11905000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
3237000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
|
13724000 | usd |
CY2022Q4 | tsvt |
Deferred Tax Assets Stock Based Compensation
DeferredTaxAssetsStockBasedCompensation
|
16719000 | usd |
CY2021Q4 | tsvt |
Deferred Tax Assets Stock Based Compensation
DeferredTaxAssetsStockBasedCompensation
|
15824000 | usd |
CY2022Q4 | tsvt |
Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
|
73719000 | usd |
CY2021Q4 | tsvt |
Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
|
71941000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
3857000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
5395000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
55719000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
|
0 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
202461000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Gross
DeferredTaxAssetsGross
|
131397000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
0 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets
DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
|
476000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
|
65181000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
|
69693000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
9266000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
|
2958000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
128014000 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
58270000 | usd |
CY2022Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
0 | usd |
CY2021Q4 | us-gaap |
Deferred Tax Liabilities
DeferredTaxLiabilities
|
0 | usd |
CY2022 | us-gaap |
Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
|
69700000 | usd |
CY2022 | tsvt |
Capitalized Research And Development Expense
CapitalizedResearchAndDevelopmentExpense
|
232100000 | usd |
CY2020Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
4403000 | usd |
CY2021 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
36000 | usd |
CY2021 | tsvt |
Unrecognized Tax Benefits Decrease Resulting From Gross Spin Off Adjustment
UnrecognizedTaxBenefitsDecreaseResultingFromGrossSpinOffAdjustment
|
4403000 | usd |
CY2021Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
36000 | usd |
CY2022 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
713000 | usd |
CY2022 | tsvt |
Unrecognized Tax Benefits Decrease Resulting From Gross Spin Off Adjustment
UnrecognizedTaxBenefitsDecreaseResultingFromGrossSpinOffAdjustment
|
0 | usd |
CY2022Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
749000 | usd |
CY2022Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | usd |
CY2022 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3911000 | shares |
CY2021 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
2570000 | shares |
CY2020 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
0 | shares |